George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
It clearly says this in the Overview tab, the Clinical Trials tab looks to be only for Trials that are on progress or completed!
‘Manufacturing of clinical supplies for a Phase 1 study is anticipated to be complete in Q1 2021 and we plan to submit an IND in Q1 2021.’
Well said physical.
Well, contrariwise, it makes me think that the BOD are so confident in the efficacy of Foralumab against Covid using the CD3 mAb that they don’t feel it’s worth pushing an extra trial at this point in time. In my opinion.
News today:
TeleTrader[03/10/2021] 12:33:00
Eli Lilly's antibody combo cuts hospitalizations, deaths by 87%
Eli Lilly and Company unveiled on Wednesday that its COVID-19 combination antibody therapy has shown an 87% efficacy in cutting the number of hospitalizations and fatal outcomes in "high-risk patients recently diagnosed with COVID-19."
The third phase of the clinical trial included 769 people older than 12, and resulted in no deaths within the group given the combination of the company's drugs bamlanivimab, and etesevimab, as opposed to the group given a placebo, the company's statement read.
The United States Food and Drug Administration (FDA) gave Eli Lilly's COVID treatment emergency use approval in February.
Just enhances the use-cases and leverage for urgent use for TILS mAbs...
Regards.
I have been busy rebalancing other rockets elsewhere, but noticed the second shoulder of the inverted TILS man pattern continuing to take shape. He just needs a shot in the arm! (Or a spray up the nose!)
LOL
Worth a read:
Healthcare and life sciences unmasked: A future accelerated by COVID-19
https://blogs.deloitte.co.uk/health/2021/01/healthcare-and-life-sciences-unmasked-a-future-accelerated-by-covid-19.html
Doh!, text copied:
Brexit - UK to fast-track drug trials to boost post-Brexit life sciences:
Drugmakers will be offered fast-tracked approvals for innovative medicines in the UK as ministers seek to build on the country’s world-leading approval of a Covid vaccine and attract life sciences companies to invest post-Brexit.
The UK’s medicines regulator will become independent of EU pharmaceutical rulemaking when Britain quits the European Medicines Agency at the end of the year, which means companies will need to apply separately to register drugs.
With ministers eager to try to refashion the UK as a post-Brexit hub for global life sciences, companies with drugs that promise to treat unmet medical needs will be offered help through the development process, including manufacturing, according to three people familiar with the situation.
Under the so-called Innovative Licensing and Access Pathway, companies are set to be offered the same rolling review of data that speeded approval of the Pfizer/BioNTech Covid-19 vaccine ahead of the rest of the world.
The move will also try to counter the threat that pharmaceutical companies will push Britain to the back of the queue for drugs given it accounts for just 3 per cent of global pharma sales.
Officials and some National Health Service staff fear that new medicines will be delayed in the UK if companies are discouraged by the extra bureaucracy from seeking approval from the UK regulator, the Medicines and Healthcare products Regulatory Agency.
One person familiar with the plans said that “life sciences can be one of the things at the centre of the UK’s post-Brexit policies”.
The UK is still locked in eleventh hour talks with the European Commission over a trade deal, with disagreements remaining over fisheries and the fair competition level playing field.
READ City watchdog admits revealing customers' details
The person added: “[Ministers] want [the UK] to be seen as a place where people come to develop innovative medicines. That’s why they were over the moon about the Covid vaccine being the first [to be approved] in the world.”
However, one industry figure, who spoke on condition of anonymity, was sceptical that a company would tailor its trials and data generation to the demands of the British market.
“A company is not going to do data just for NICE [National Institute for Health and Care Excellence] when the UK is a fraction of global pharma sales; it’s not going to spend millions on studies just for the UK,” they added.
The executive argued that a far bigger overhaul was needed of the framework that NICE uses to calculate value-for-money. A review of the agency’s methodology is under way and any changes are expected to be announced in the spring.
Sorry, bad link, try this:
Brexit - UK to fast-track drug trials to boost post-Brexit life sciences:
https://www.ft.com/content/424ad1e2-9984-4e10-9ffa-0ed08f4e598b
Nice report. We are definitely in the decade of Life Sciences, and governments are falling over themselves to help speed things up.
I found this, from the Financial Times in Dec:
Brexit - UK to fast-track drug trials to boost post-Brexit life sciences:
https://www.google.co.uk/amp/s/amp.ft.com/content/424ad1e2-9984-4e10-9ffa-0ed08f4e598b
I am hoping for news sooner rather than later of an emergency phase 2 Foralumab Covid trial in the US (+?). Logically that would absolutely deserve a re-rate up to ‘at least’ the same price range as SNG (175+). That would be the correct holding stage before a bigger launch later this year/early next year, in my opinion.
After some reading up on this earlier, it’s no wonder that the majority of mAbs are currently sitting on the shelves unused during the pandemic. Despite the need for the infusion centres to be reserved for medically Covid vulnerable cancer patients, the very high toxicity from infusion results in a long intensive process that needs to be closely monitored and can have bad effects on the patient. Never going to be an option for most people (without their own personal Dr’s/clinics).
Hi bubbles2,
yes, that’s the consensus of opinion from the experts, in relation to Covid the Foralumab phase 1 results should be similar for any Covid variant or other serious respiratory disease. That’s because Foralumab is preventing/reducing the cytokine storm, which is where the body’s own immune system goes haywire and results in massive damage to the lungs/airways. It’s the rapid destruction of cells in the airway that clog up and damage the lungs and result in increasingly dangerously lower and lower levels of oxygen in the blood. This new method of anti-inflammation can also be targeted to different areas: nasally/inhalation to treat the airways as for other respiratory viruses/diseases, nasally to cross the brain barrier for the various brain diseases, e.g. Alzheimer’s, and orally to target the small intestine for digestive diseases like Crohn’s and IBS. The possibility for much more effective and less toxic treatment for so many different illnesses, and also to use this targeted dosing for other monoclonal antibody drugs (by other companies on a royalty basis due to the TILS patent) is simply a breathtaking proposition, in my opinion.
Hi MIKESM,
I agree, absolutely, along with Lupus which my wife suffers from. In fact, I have other friends and family who could benefit from the TILS pipeline further down the line which just makes me feel even better about my investment here.
Regards,
Thanks TradePhoenix,
...and those results are absolutely pale against the recent Foralumab Phase 1 results plus the 10 - 50x efficacy improvement with drastically reduced toxicity possibilities for generic mAb dosing using the ‘patented’ TILS nasal/inhaled/oral platform. The sky really is the limit for the TILS rocket!
Plus, it all just makes a complete mockery of the de-ramping posts from certain suspicious individuals on this board...
I couldn’t agree more TradePhoenix
LSE need to Wake Up! and smell the coffee. It’s no wonder so many pi’s, myself included, are turning more to Australian and Canadian listed stocks, they are a far less smelly experience. Anyone that spends enough time comparing markets will quickly come to the same conclusions, in my opinion.
>> 300k buy!
...and the share price keeps dropping. Just ludicrous.
I must admit, I do feel that in the not too distant future TILS will need a lot more employees, however that happens. It appears some of the BOD do have experience in growing companies though.
Very interesting idea D-Geeman. Are there any candidates you have spotted or have in mind?
I find the AIM market one of the most interesting, there’s always some action taking place, and new baby rockets to research...
Plus my theory that on average the smaller, cheaper penny rockets lose less in a sudden downturn has ‘so far’ proven to be viable.